Contemporary prostate cancer survival in Ireland: a national benchmark analysis using IPCOR data
Abstract
Background: Prostate cancer (PCa) is the most commonly diagnosed cancer among men in Ireland, with over 4,000 new cases annually. Population-based survival estimates are needed to benchmark outcomes and inform service planning in the modern diagnostic and treatment era. The Irish Prostate Cancer Outcomes Research (IPCOR) registry is a national multicentre cohort capturing clinical data across public and private hospitals. Long-term survival outcomes in this cohort have not been comprehensively reported. While survival is high, outcomes remain heterogeneous, highlighting the need for subgroup analysis. The aim was to estimate overall survival (OS) and examine variation by risk, treatment, and socioeconomic status.
Methods: IPCOR data were linked to the National Cancer Registry Ireland survival update. OS was estimated using Kaplan–Meier methods and compared using log-rank tests. Multivariable Cox regression identified predictors of mortality, adjusting for age, CAPRA risk group, primary treatment, and deprivation index.
Results: Among 6816 men, median follow-up was 103 months (IQR 94-112). Five- and ten-year OS rates were 89.6% and 79.5%. Survival differed by CAPRA risk (p < 0.001), with 5-year OS of 97.6%, 95%, and 80% for low, intermediate, and high risk. Survival also varied by treatment (p < 0.001), highest with radical prostatectomy (RP) (97.5%) and lowest with androgen deprivation therapy (62.2%). No differences were observed by deprivation (p = 0.35). In adjusted analyses, intermediate- and high-risk disease (HR 1.78, 95% CI 1.38-2.29 and HR 4.25, 95% CI 3.29-5.49), RP (HR 0.30, 95% CI 0.23-0.40) and radiotherapy (HR 0.54, 95% CI 0.44-0.64) vs active surveillance, and age (HR 1.07, 95% CI 1.06-1.08), were associated with mortality.
Conclusions: This study provides a national benchmark of contemporary PCa survival in Ireland. Variation by risk and treatment highlights opportunities to enhance quality of care through optimising treatment selection and care pathways.
Key messages: • This study provides the first contemporary national benchmark of prostate cancer survival in Ireland, supporting monitoring of outcomes and informing service planning.
• Variation in survival by risk and treatment highlights opportunities to optimise treatment selection and enhance prostate cancer care in Ireland.
Related
- Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real‐World Analysis From REALYSA, a LYSA Cohort
- A National Survey of Kidney Supportive Care Services in Ireland
- Public Attitudes Towards Alcohol and Drug Prevention in Ireland: Findings from a National Survey
- Qualitative Evaluation of Ireland’s National Infant RSV Immunisation Programme
- Predicting MCI-to-Alzheimer’s Conversion: A Systematic Benchmark of Classical, Machine Learning, and Deep Survival Models
BibTeX
@article{byrne2026contemporary,
title = {{Contemporary prostate cancer survival in Ireland: a national benchmark analysis using IPCOR data}},
author = {E Byrne and N Gordon and L Hoang and W Farooq and W Watson and P Fitzpatrick and D Galvin},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.170},
url = {https://doi.org/10.1093/eurpub/ckag169.170},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Contemporary prostate cancer survival in Ireland: a national benchmark analysis using IPCOR data
AU - E Byrne
AU - N Gordon
AU - L Hoang
AU - W Farooq
AU - W Watson
AU - P Fitzpatrick
AU - D Galvin
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.170
UR - https://doi.org/10.1093/eurpub/ckag169.170
AB - Background: Prostate cancer (PCa) is the most commonly diagnosed cancer among men in Ireland, with over 4,000 new cases annually. Population-based survival estimates are needed to benchmark outcomes and inform service planning in the modern diagnostic and treatment era. The Irish Prostate Cancer Outcomes Research (IPCOR) registry is a national multicentre cohort capturing clinical data across public and private hospitals. Long-term survival outcomes in this cohort have not been comprehensively reported. While survival is high, outcomes remain heterogeneous, highlighting the need for subgroup analysis. The aim was to estimate overall survival (OS) and examine variation by risk, treatment, and socioeconomic status. Methods: IPCOR data were linked to the National Cancer Registry Ireland survival update. OS was estimated using Kaplan–Meier methods and compared using log-rank tests. Multivariable Cox regression identified predictors of mortality, adjusting for age, CAPRA risk group, primary treatment, and deprivation index. Results: Among 6816 men, median follow-up was 103 months (IQR 94-112). Five- and ten-year OS rates were 89.6% and 79.5%. Survival differed by CAPRA risk (p < 0.001), with 5-year OS of 97.6%, 95%, and 80% for low, intermediate, and high risk. Survival also varied by treatment (p < 0.001), highest with radical prostatectomy (RP) (97.5%) and lowest with androgen deprivation therapy (62.2%). No differences were observed by deprivation (p = 0.35). In adjusted analyses, intermediate- and high-risk disease (HR 1.78, 95% CI 1.38-2.29 and HR 4.25, 95% CI 3.29-5.49), RP (HR 0.30, 95% CI 0.23-0.40) and radiotherapy (HR 0.54, 95% CI 0.44-0.64) vs active surveillance, and age (HR 1.07, 95% CI 1.06-1.08), were associated with mortality. Conclusions: This study provides a national benchmark of contemporary PCa survival in Ireland. Variation by risk and treatment highlights opportunities to enhance quality of care through optimising treatment selection and care pathways. Key messages: • This study provides the first contemporary national benchmark of prostate cancer survival in Ireland, supporting monitoring of outcomes and informing service planning. • Variation in survival by risk and treatment highlights opportunities to optimise treatment selection and enhance prostate cancer care in Ireland.
SN - 1101-1262
SN - 1464-360X
ER -